Deferred Tax Assets, Operating Loss Carryforwards of Intra-Cellular Therapies, Inc. from 31 Dec 2012 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Intra-Cellular Therapies, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2012 to 31 Dec 2024.
  • Intra-Cellular Therapies, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $130,066,000, a 6.2% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Intra-Cellular Therapies, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $130,066,000 -$8,619,000 -6.2% 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q4 2023 $138,685,000 -$29,921,000 -18% 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q4 2022 $168,606,000 +$31,045,000 +23% 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q4 2021 $137,561,000 +$51,809,846 +60% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q4 2020 $85,751,154 +$36,082,922 +73% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q4 2019 $49,668,232 +$5,795,666 +13% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q4 2018 $43,872,566 +$3,125,977 +7.7% 31 Dec 2018 10-K 02 Mar 2020 2019 FY
Q4 2017 $40,746,589 -$8,881,063 -18% 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q4 2016 $49,627,652 -$27,113,546 -35% 31 Dec 2016 10-K 01 Mar 2018 2017 FY
Q4 2015 $76,741,198 +$41,871,029 +120% 31 Dec 2015 10-K 01 Mar 2017 2016 FY
Q4 2014 $34,870,169 +$12,523,307 +56% 31 Dec 2014 10-K 25 Feb 2016 2015 FY
Q4 2013 $22,346,862 +$14,016,923 +168% 31 Dec 2013 10-K 12 Mar 2015 2014 FY
Q4 2012 $8,329,939 31 Dec 2012 10-K 25 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.